Antiandrogens Market Report: Trends, Forecast and Competitive Analysis to 2030

The global antiandrogens market is expected to reach an estimated $8.7 billion by 2030 with a CAGR of 6.8% from 2024 to 2030.

The major drivers for this market are increasing prevalence of prostate cancer and rising disposable incomes, growing awareness about androgen-related conditions, as well as, technological developments made in drug delivery system. The future of the global antiandrogens market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.

The study includes a forecast for the global antiandrogens by type, indication, distribution channel, and region.

Antiandrogens Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Steroidal
• Non-Steroidal

Antiandrogens Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

• Prostate Cancer
• Benign Prostatic Hyperplasia
• Hirsutism
• Hyperandrogenism
• Others

Antiandrogens Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Antiandrogens Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Asia Pacific
• The Rest of the World

List of Antiandrogens Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies antiandrogens companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the antiandrogens companies profiled in this report include:

• Pfizer
• Astellas Pharma
• F. Hoffmann-La Roche
• AstraZeneca
• Abbott Laboratories
• Takeda Pharmaceutical Company
• OSI Pharmaceuticals
• Genentech
• Novartis

Non-steroidal will remain the larger segment over the forecast period.

North America is expected to witness highest growth over the forecast period due to existence of well-established healthcare infrastructure, growing awareness about the androgen-related disorders, and favorable reimbursement policies.

Features of the Global Antiandrogens Market

- Market Size Estimates: Antiandrogens market size estimation in terms of value ($B).

• Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
• Segmentation Analysis: Antiandrogens market size by type, indication, distribution channel, and region in terms of value ($B).
• Regional Analysis: Antiandrogens market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, indication, distribution channel, and regions for the antiandrogens market.
• Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the antiandrogens market size?
Answer: The global antiandrogens market is expected to reach an estimated $8.7 billion by 2030.

Q2. What is the growth forecast for antiandrogens market?
Answer: The global antiandrogens market is expected to grow with a CAGR of 6.8% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the antiandrogens market?
Answer: The major drivers for this market are increasing prevalence of prostate cancer and rising disposable incomes, growing awareness about androgen-related conditions, as well as, technological developments made in drug delivery system.

Q4. What are the major segments for antiandrogens market?
Answer: The future of the global antiandrogens market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.

Q5. Who are the key antiandrogens market companies?
Answer: Some of the key antiandrogens companies are as follows:

• Pfizer
• Astellas Pharma
• F. Hoffmann-La Roche
• AstraZeneca
• Abbott Laboratories
• Takeda Pharmaceutical Company
• OSI Pharmaceuticals
• Genentech
• Bristol-Myers Squibb
• Novartis

Q6. Which antiandrogens market segment will be the largest in future?
Answer: The publisher forecasts that non-steroidal will remain the larger segment over the forecast period.

Q7. In antiandrogens market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period due to existence of well-established healthcare infrastructure, growing awareness about the androgen-related disorders, and favorable reimbursement policies.

Answer: Yes, the publisher provides 10% customization without any additional cost.

This report answers the following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the antiandrogens market by type (steroidal and non-steroidal), indication (prostate cancer, benign prostatic hyperplasia, hirsutism, hyperandrogenism, and others), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?


This product will be delivered within 1-3 business days.